Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the ...

New research published by the European Federation of Industries and Associations (EFPIA) provides in-depth analysis of the ...

French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from ...

Denmark's health reform targets chronic disease care, health inequalities, and innovation, with measures like chronic care ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). Revuforj is the first ...

Junshi Biosciences' Loqtorzi has received MHRA approval for NPC and ESCC, marking the first NPC drug and a PD-L1-independent ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...

Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) ...

US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study ...

Amferia's peptide-based hydrogel boosts antibiotic effectiveness by up to 64 times against resistant bacteria, stabilizing ...

Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 Dec.

Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...